HKI/paclitaxel vs Trastuzumab/paclitaxel in metastatic breast cancer

• Research type

  Research Study

• Full title

  A Phase 3, Randomised, Open Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer

• IRAS ID

  22015

• Eudract number

  2008-007803-10

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  NCT00915018

• Research summary

  N/A

• REC name

  East Midlands - Leicester South Research Ethics Committee

• REC reference

  09/H0402/83

• Date of REC Opinion

  23 Sep 2009

• REC opinion

  Further Information Favourable Opinion